Skip to content

Clinical Assessment of DAILIES TOTAL1® (DT1) Multifocal

DAILIES TOTAL1® Multifocal Clinical Assessment in Challenging Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02871375
Enrollment
170
Registered
2016-08-18
Start date
2016-08-30
Completion date
2016-11-14
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Error

Keywords

myopia, presbyopia

Brief summary

The purpose of this study is to evaluate DAILIES TOTAL1® Multifocal (DTl MF) contact lenses in current multifocal contact lens wearers with symptoms of end of day discomfort compared to their habitual multifocal contact lens correction.

Interventions

Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)

DEVICEHabitual multifocal contact lenses

Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality

Sponsors

Alcon, a Novartis Company
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Must sign an informed consent document; * Current daily wearer of soft multifocal contact lenses for at least 6 months with symptoms of contact lens discomfort as defined by the prescreening Eligibility Questionnaire; * Requires a near spectacle add of +0.50 to +2.50 diopters (D) (inclusive); * Requires lenses within the power range of study lenses to be fitted; * Best corrected VA (BCVA) of 20/30 (0.2 logarithmic minimum angle of resolution \[logMAR\]) or better in each eye at distance; * Willing to wear study lenses for a minimum of 5 days per week, 6 hours per day, and attend all study visits; * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Any eye condition that contraindicates wearing contact lenses as determined by the Investigator; * Any use of medications for which contact lens wear could be contraindicated, as determined by the Investigator; * Monocular (only one eye functional) or fit with only 1 lens; * Fitted with monovision; * Prior refractive surgery (e.g., laser vision correction, photorefractive keratectomy, etc.); * History of herpetic keratitis, ocular surgery, or irregular cornea; * Currently wearing DT1 MF contact lenses; * Other protocol-defined

Design outcomes

Primary

MeasureTime frameDescription
Binocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm)Day 14, each productVisual Acuity (clarity or sharpness of vision) was measured at high contrast level. HC/HI VA was assessed binocularly (both eyes together) at 80 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR). A lower logMAR value indicates better visual acuity.

Secondary

MeasureTime frameDescription
Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) ScoreDay 14, each productThe abbreviated CLDEQ-8 is an 8-item questionnaire used to assess comfort and dryness. Total CLDEQ-8 score ranged from 0 to 37, where a lower score represented less symptomology.

Participant flow

Recruitment details

Subjects were recruited from 11 study centers located in the United States.

Pre-assignment details

Of the 170 enrolled, 2 subjects were exited as screen failures prior to randomization. An additional 2 subjects were randomized in error but not exposed. This reporting group includes all randomized and exposed subjects (166).

Participants by arm

ArmCount
Overall
Delefilcon A multifocal contact lenses and subject's habitual multifocal contact lenses worn bilaterally during Period 1 and Period 2 in a crossover assignment.
166
Total166

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1, First 14 Days of WearInclusion criteria not met01

Baseline characteristics

CharacteristicOverall
Age, Continuous52.0 years
STANDARD_DEVIATION 5.14
Sex: Female, Male
Female
128 Participants
Sex: Female, Male
Male
38 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 1700 / 1650 / 166
other
Total, other adverse events
0 / 1700 / 1650 / 166
serious
Total, serious adverse events
0 / 1700 / 1650 / 166

Outcome results

Primary

Binocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm)

Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HC/HI VA was assessed binocularly (both eyes together) at 80 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR). A lower logMAR value indicates better visual acuity.

Time frame: Day 14, each product

Population: Full Analysis Set. Number Analyzed is the number of subjects with non-missing responses.

ArmMeasureValue (MEAN)Dispersion
DT1 MFBinocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm)-0.07 logMARStandard Deviation 0.1
Habitual MFBinocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm)-0.09 logMARStandard Deviation 0.1
Secondary

Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score

The abbreviated CLDEQ-8 is an 8-item questionnaire used to assess comfort and dryness. Total CLDEQ-8 score ranged from 0 to 37, where a lower score represented less symptomology.

Time frame: Day 14, each product

Population: Full Analysis Set. Number Analyzed is the number of subjects with non-missing responses.

ArmMeasureGroupValue (MEAN)Dispersion
DT1 MFContact Lens Dry Eye Questionnaire-8 (CLDEQ-8) ScorePeriod One9.9 units on a scaleStandard Deviation 5.4
DT1 MFContact Lens Dry Eye Questionnaire-8 (CLDEQ-8) ScorePeriod Two11.6 units on a scaleStandard Deviation 6.3
DT1 MFContact Lens Dry Eye Questionnaire-8 (CLDEQ-8) ScoreOverall10.7 units on a scaleStandard Deviation 5.9
Habitual MFContact Lens Dry Eye Questionnaire-8 (CLDEQ-8) ScorePeriod One17.0 units on a scaleStandard Deviation 7.1
Habitual MFContact Lens Dry Eye Questionnaire-8 (CLDEQ-8) ScorePeriod Two13.0 units on a scaleStandard Deviation 6.2
Habitual MFContact Lens Dry Eye Questionnaire-8 (CLDEQ-8) ScoreOverall14.9 units on a scaleStandard Deviation 6.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026